Related by context. All words. (Click for frequent words.) 68 Tyrima 68 Vidaza ® 67 CYT# potent vascular disrupting 67 liposomal formulation 67 JAK2 inhibitor 67 MAGE A3 ASCI 67 erlotinib Tarceva ® 67 ganetespib 67 novel VDA molecule 67 multicenter Phase II 67 bortezomib Velcade 66 Aplidin 66 antiangiogenic therapy 66 receptor tyrosine kinase inhibitor 66 evaluating tivozanib 66 CBLC# 66 oral prodrug 66 potent antiproliferative 66 investigational monoclonal antibody 66 MGd 66 liposomal doxorubicin 66 IAP inhibitor 66 AKT inhibitor 66 IMiDs ® 66 receptor inhibitor 66 alvespimycin 66 IMiDs R 66 IMA# 66 metaglidasen 66 pan HDAC inhibitor 66 pharmacodynamic markers 66 OMP #M# 66 HGS ETR1 mapatumumab 65 HuMax EGFr 65 xenograft models 65 selective modulator 65 histone deacetylase inhibitor 65 Sudhir Agrawal D.Phil 65 IMiDs ® compound 65 taxane resistant 65 neuronal nicotinic receptor NNR 65 retaspimycin hydrochloride 65 galiximab 65 Exherin TM 65 delafloxacin 65 Azedra 65 relapsed MM 65 Hsp# inhibitor 65 HuLuc# 65 ENMD # 65 Annamycin 65 Kahalalide F 65 Zalypsis 65 imatinib Gleevec ® 65 MTP inhibitor 65 JAK2 inhibitors 65 CRLX# 65 fosbretabulin 65 neratinib 65 antisense inhibitors 65 PEGPH# 65 nanopharmaceutical 65 histone deacetylase HDAC inhibitor 65 selective kinase inhibitor 64 Quinamed 64 mTOR inhibitors 64 potent cytotoxic 64 dasatinib Sprycel 64 XL# inhibits 64 Darinaparsin 64 HGS# 64 chimeric monoclonal antibody 64 Omacetaxine 64 Enzastaurin 64 elotuzumab 64 acadesine 64 preclinically 64 ALK inhibitors 64 Pimavanserin 64 CORT # 64 peptidic 64 antimitotic 64 candidate CRLX# 64 CCR5 antagonist 64 microtubule inhibitor 64 systemically administered 64 Panzem NCD 64 Smac mimetics 64 immunomodulating 64 sunitinib Sutent ® 64 non nucleoside HCV 64 dasatinib Sprycel ® 64 S/GSK# 64 HGS ETR2 64 CINQUIL 64 kidney urologic 64 proteasome inhibitors 64 irreversible inhibitor 64 Gleevec resistant 64 immunomodulator 64 demonstrated antitumor activity 64 investigational humanized monoclonal antibody 64 targeted antifolate 64 HDACi 64 selectively inhibited 64 compound AEZS 64 GRN# 64 tubulin inhibitor 64 Tarvacin TM 64 telomerase inhibitor 64 Panzem R NCD 64 preclinical efficacy 63 Phase 1a clinical 63 inhaled TPI ASM8 63 cediranib 63 tanespimycin 63 Apoptone 63 Aplidin R 63 Locked Nucleic Acid LNA 63 huC# DM4 63 CG# [003] 63 PEG SN# 63 cisplatin resistant 63 Tß4 63 Onconase 63 Blinatumomab 63 trastuzumab Herceptin R 63 vascular disrupting agent 63 Deforolimus 63 HGS ETR1 63 kinase inhibition 63 visilizumab 63 gefitinib Iressa 63 orally bioavailable 63 targeting CD# 63 HCV protease inhibitors 63 cisplatin gemcitabine 63 SAR# [004] 63 protein kinase inhibitors 63 pharmacodynamic effects 63 tumor subtypes 63 orally administered inhibitor 63 Smac mimetic 63 AEG# 63 anti CD3 63 mecamylamine 63 mediated inhibition 63 PKC# 63 Pertuzumab 63 antagomirs 63 fusion enhancers 63 virus HCV protease inhibitor 63 Carfilzomib 63 ceftazidime 63 Hsp# inhibition 63 GW# [003] 63 HCV NS5B polymerase 63 Ceflatonin 63 OncoVex 63 NEUGENE 63 Thiovir 63 vinca alkaloid 63 CTAP# Capsules 63 NS5B polymerase 63 pharmacokinetic interactions 63 Pharmacokinetics PK 63 cisplatin carboplatin 63 Ophena TM 63 novel immunomodulatory 63 D aspartate NMDA receptor 63 triphendiol 63 HepDirect prodrug 63 metastatic colorectal 63 anionic backbone 63 immune modulating 63 cytotoxic T lymphocyte 63 farletuzumab 63 interleukin IL -# 63 ALN TTR 63 DermaVir Patch 63 riociguat 63 histone deacetylase HDAC 63 Squalamine 63 Hsp# Inhibitor 63 alkylating agent 63 monoclonal anti 63 preclinical pharmacokinetic 63 targeted radiotherapeutic 63 PI3K/mTOR 63 anti leukemic 63 YONDELIS 63 NEUGENE antisense 63 Akt inhibitor 63 FOLOTYN ® 63 trastuzumab Herceptin ® 63 MVA MUC1 IL2 63 Cloretazine 63 generation purine nucleoside 63 HCD# [002] 62 murine models 62 Luteinizing Hormone Releasing Hormone 62 pathophysiological effects 62 alpha#beta# 62 crizotinib PF # 62 accumulate preferentially 62 5 HT2A serotonin 62 sorafenib tablets 62 GRNVAC1 62 FUSILEV enhances 62 gamma secretase inhibitors 62 investigational protease inhibitor 62 anti amnesic 62 solithromycin 62 chemotherapeutic drug 62 novel peptide 62 LAB CGRP 62 Rigel R# 62 RiVax 62 protein tyrosine phosphatase 1B 62 pertuzumab 62 Curaxin 62 cyclophilin inhibitor 62 VA# [002] 62 BMS # 62 double blinded randomized 62 agonistic human 62 NSCLC tumors 62 multicenter Phase III 62 cilengitide 62 Omacetaxine mepesuccinate 62 AAG geldanamycin analog 62 YONDELIS R 62 ongoing Phase 1b 62 Valproic acid 62 intravenously administered 62 diagnostic biomarker 62 Sapacitabine 62 NS4A 62 K ras mutations 62 Fc fusion protein 62 GRNOPC1 contains 62 IAP inhibitors 62 TAKSTA 62 neuroprotectant 62 PSMA ADC 62 ROTARIX 62 isoform selective 62 nilotinib Tasigna ® 62 XmAb# 62 IMC A# 62 immune modulatory 62 BiTE R 62 histone deacetylase inhibitors 62 rALLy clinical trial 62 Proellex TM 62 Clusterin 62 multicenter randomized placebo controlled 62 liposome formulation 62 mapatumumab 62 bevacizumab Avastin ® 62 oral Janus kinase 62 trabectedin 62 lenalidomide Revlimid R 62 biased ligand 62 CCR2 62 Safinamide 62 mGluR5 NAM 62 CR# vcMMAE 62 #beta estradiol 62 EGFR TKIs 62 Oral NKTR 62 Xanafide 62 potent suppressor 62 vapreotide acetate 62 ospemifene 62 refractory gout 62 heparanase 62 mouse xenograft models 62 nucleoside analogs 62 relapsing multiple sclerosis 62 multitargeted 62 pharmacodynamic PD 62 nucleotide analog 62 forodesine 62 SNT MC# 62 monoclonal antibody conjugated 62 OHR/AVR# 62 busulfan 62 nucleotide analogue 62 highly selective endothelin 62 NB S# strontium malonate 62 Traficet EN 62 tigecycline 62 JAK inhibitor 62 SPRYCEL ® 62 CLORETAZINE TM VNP#M 62 HQK 62 Cyclin E 62 Phase 1b trial 62 selective orally bioavailable 62 mda 7 62 GAMMAGARD 62 pegylated liposomal doxorubicin 62 papillary renal cell carcinoma 62 ritonavir boosted 62 nucleoside analog 62 HER2 overexpression 62 Tarceva TM 62 gemcitabine Gemzar 62 CDK inhibitor 62 pentostatin 62 CXB# 62 formerly LymphoStat B 62 synthetic peptides 62 proteasome inhibitor 62 corticosteroid dexamethasone 62 recurrent glioblastoma multiforme 62 Cloretazine R 62 thalidomide Thalomid 62 Factor Receptor 62 CYP#A# CYP#D# 62 CEQ# 62 bronchodilatory 62 Immunotherapeutic 62 sorafenib Nexavar 62 radiotherapeutic 62 OvaRex R 62 ToGA 62 cytokine refractory 62 pomalidomide 62 DAVANAT 62 oral ghrelin agonist 62 cyclic peptide 62 TLR9 agonist 62 Phase #b/#a clinical 62 Afatinib 61 protein kinase inhibitor 61 Bayer HealthCare Onyx Pharmaceuticals 61 orally dosed 61 lymphomas leukemias 61 TLK# 61 PI3K inhibitor 61 mGluR2 NAM 61 APOPTONE 61 small molecule defensin 61 EXPLORE Xa 61 oral deforolimus 61 oral antiviral 61 phase IIa clinical 61 florbetaben 61 NS#/#A protease 61 anti mitotic 61 depsipeptide 61 trastuzumab emtansine T DM1 61 tolerability pharmacokinetics 61 PDX pralatrexate 61 HCV protease 61 plasma kallikrein inhibitor 61 Capesaris 61 therapeutic monoclonal antibody 61 potent topoisomerase II 61 VitiGam 61 selective inhibitors 61 phosphatidylserine PS targeting 61 acyclovir Lauriad R 61 APTIVUS r 61 Teriflunomide 61 MKC# MT 61 reversible inhibitor 61 GRN#L 61 Pharmacokinetic studies 61 Amplimexon 61 SPC# [001] 61 peptide conjugated 61 Neulasta ® 61 OXi# 61 epigenetic therapies 61 molecularly targeted 61 PI3K Akt 61 pharmacokinetics pharmacodynamics 61 phase Ib 61 pharmacokinetic PK study 61 MEK inhibitor 61 blinded randomized placebo controlled 61 erlotinib Tarceva 61 poly ADP ribose polymerase 61 novel emulsion formulation 61 Angiolix 61 Kinoid 61 RGB # 61 PI3K/Akt pathway inhibitor 61 DNA methyltransferase inhibitors 61 cortisol synthesis 61 monoclonal antibody mAb 61 INS# [001] 61 Marqibo TM 61 isatoribine 61 MYLOTARG 61 clevidipine 61 druggable targets 61 Curaxin CBLC# 61 Dapagliflozin 61 polymerase inhibitor 61 ESBA# 61 novel topoisomerase 61 CCR5 inhibitor 61 M2 subunit 61 Poly ICLC 61 ELACYT 61 evaluating REVLIMID 61 ALB # 61 orally inhaled migraine 61 PRT# 61 benzimidazole 61 epothilones 61 FOLFOX6 chemotherapy regimen 61 entinostat 61 factor TNF 61 Cannabinor 61 Multimeric 61 TransVax tm 61 pharmacokinetics PK 61 novel anticancer 61 Ostabolin C TM 61 TRO# 61 telomerase inhibition 61 epithelial tumors 61 sorafenib Nexavar ® 61 Fibroblast Growth Factor Receptor 61 novel orally bioavailable 61 TransVax ™ 61 estramustine 61 thrombin receptor 61 intravesical instillation 61 TG# [003] 61 peptide receptor 61 ImmunoVEX HSV2 61 bortezomib Velcade R 61 prescribed proton pump 61 antibody MAb 61 Dasatinib 61 anti androgens 61 ALN TTR# 61 vidofludimus 61 OncoVEX GM CSF 61 5 HT6 receptor 61 KRN# 61 TPI ASM8 61 CCR9 antagonist 61 iobenguane 61 CCX# 61 TriRima 61 Zolinza 61 potently inhibited 61 Solorel TM 61 drug zotarolimus 61 intratumoral 61 selective antagonist 61 Interferon alpha 61 IMC #B 61 inecalcitol 61 signal transduction inhibitors 61 aurora kinase 61 hypoxia activated prodrug 61 redox active 61 A3 adenosine receptor 61 matrix metalloproteases 61 vascular disrupting 61 biomarker identification 61 parthenolide 61 antitumoral 61 EDEMA3 61 delipidation 61 anti CD3 antibody 61 resolvin 61 aurora kinase inhibitor 61 alpha folate receptor 61 Genz # 61 adalimumab Humira 61 ascending dose 61 thymidylate synthase 61 Protein Kinase C 61 anticancer therapeutics 61 taxane derivative 61 NXL# 61 cannabinor 61 2 methoxyestradiol 61 peptide antigens 61 potent inducer 61 ara C 61 infliximab Remicade 61 immuno modulatory 61 velafermin 61 phase IIb clinical 61 PHX# 61 peptibody 61 GAP #B# 61 antiangiogenic agent 61 radiolabeled TM# 61 Bezielle 61 systemic RNAi therapeutic 61 CA4P 61 antiangiogenesis 61 peptidomimetic 61 NATRECOR ® 61 telomerase inhibitor drug 61 favorable pharmacokinetic profile 61 sitaxsentan 61 antitumour 61 BRIM2 61 potently inhibit 61 myelofibrosis polycythemia vera 61 molecular determinants 61 astemizole 61 null responder 61 non metastatic osteosarcoma 61 lenalidomide dexamethasone 61 mertansine 60 lapatinib Tykerb 60 immunomodulators 60 humanized monoclonal antibodies 60 Adenoscan R 60 candidate deforolimus 60 NS5A 60 flavopiridol 60 HCV protease inhibitor 60 canakinumab 60 gemcitabine Gemzar ® 60 OMP #R# 60 histone deacetylase 60 TLR8 agonist 60 paclitaxel Taxol 60 targeting PCSK9 60 Tumor Necrosis Factor 60 PDE4 inhibitor 60 BNC# 60 relapsed ALL 60 teriflunomide 60 VNP#M 60 dopamine D2 60 GMX# 60 p# inhibitor 60 nanomolar 60 potent anticancer 60 afamelanotide 60 obatoclax 60 castrate resistant prostate cancer 60 immunomodulatory properties 60 triggers apoptosis programmed 60 imatinib resistant 60 plasma kallikrein 60 subcutaneous SC 60 oral Azacitidine 60 immunotoxin 60 TLR8 60 small molecule activators 60 geldanamycin 60 PXD# 60 sulodexide 60 ON #.Na 60 PSN# [002] 60 erythropoietic 60 Elotuzumab 60 small molecule tyrosine 60 pharmacodynamic properties 60 alpha antagonist 60 immunomodulatory effects 60 safety tolerability pharmacokinetic 60 Epidermal Growth Factor Receptor 60 Spiegelmer ® 60 TACI Ig 60 Janus Kinase 60 telomerase therapeutic 60 camptothecin 60 Dacogen decitabine 60 Bruton tyrosine kinase Btk 60 IRX 2 60 pharmacokinetic pharmacodynamic PK PD 60 uric acid lowering 60 Solazed TM 60 #I TM# 60 oral picoplatin 60 lipopeptide 60 anticancer agent 60 non nucleoside inhibitor 60 Tesetaxel 60 oral JAK1 60 Aurora kinase inhibitor 60 insulin sensitizers 60 vemurafenib 60 biliary tract cancer 60 enzyme inhibitor 60 DXL# 60 enzastaurin 60 CA9 SCAN 60 potent anti angiogenic 60 RNAi therapeutic targeting 60 anticancer agents 60 SGLT 2 60 refractory chronic lymphocytic 60 GVAX ® 60 bleomycin 60 fibrotic disease 60 tumorigenicity 60 pharmacodynamics 60 humanized monoclonal antibody 60 Phase IIb III 60 Perceiva 60 interferon gamma 1b 60 humanized monoclonal 60 gamma secretase inhibitor 60 docetaxel Taxotere R 60 phase IIb study 60 irinotecan chemotherapy 60 trastuzumab Herceptin 60 urate lowering 60 potent inhibitor 60 vorinostat 60 biochemical assays 60 uricase 60 mTOR inhibition 60 immune stimulatory 60 neurokinin 1 60 myeloproliferative disorders 60 Azacitidine 60 trastuzumab DM1 60 P#X# antagonist 60 MEK inhibitors 60 viral tropism 60 NP2 Enkephalin 60 M1 muscarinic 60 selective serotonin 2C receptor 60 PROCHYMAL 60 adrenergic regulation 60 indibulin 60 signal transduction inhibitor 60 Triapine 60 genotypic resistance 60 5alpha reductase 60 siRNAs targeting 60 enkephalin 60 transgenic rats 60 anticancer compound 60 predictive biomarkers 60 BRAF inhibitors 60 Ganetespib 60 Trastuzumab DM1 60 TMC# C# 60 sunitinib malate 60 dose escalation clinical 60 thetreatment 60 TKB# 60 antiangiogenic activity 60 imetelstat 60 hematopoietic cancers 60 CGEN # 60 cytotoxicity assays 60 chemokine receptor 60 humanized antibody 60 NOD SCID mice 60 lumiliximab 60 somatostatin 60 EGFR HER2 60 HCV polymerase 60 registrational Phase 60 Miraxion Amarin lead 60 nicotinic acetylcholine receptor 60 antiproliferative effects 60 selective androgen receptor modulator 60 alkylating 60 RAS MAPK pathway 60 HER2 positive metastatic breast 60 intranasal delivery 60 relapsed multiple myeloma 60 ABSSSI 60 investigational pan BCR 60 Angiotensin Converting Enzyme 60 Liposomal 60 PTH analogue 60 siRNA therapeutic 60 PSN# [001] 60 masitinib 60 relapsed refractory multiple myeloma 60 Archexin 60 bovine thrombin 60 optical biosensors 60 Trandolapril 60 atherosclerosis regression 60 cytoprotective 60 imexon 60 vaccine GRNVAC1 60 synthetic retinoid 60 BMS# 60 Kinase Inhibitor 60 sulfonylhydrazine class 60 hA# 60 antitumor 60 5 fluorouracil leucovorin 60 siRNA binds 60 potent inhibition 60 Alexza Staccato 60 selective inhibition 60 antineoplastic 60 Voreloxin 60 TLE3 60 histologies 60 interferon alfa 60 dacetuzumab 60 Fx #A 60 Vaxfectin TM 60 #beta HSD 1 60 immunomodulatory 60 chlamydial 60 dexamethasone Decadron 60 ADI PEG 60 CD# monoclonal antibody 60 potentially hepatotoxic 60 interferon IFN 60 Trofex 60 AEGR 60 HCV replicon 60 subcutaneous immunoglobulin 60 apoptosis inducer 60 PrevOnco ™ 60 antitumor effects 60 BCR ABL inhibitors 60 BEZ# 60 cyclooxygenase COX 60 AVONEX ® 60 gemcitabine carboplatin 60 anti angiogenic drugs 60 candidates Azedra TM 60 latrepirdine 60 inhibit viral replication 60 PANVAC VF 60 phase IIa 60 oral rivaroxaban 60 Hsp# inhibitors 60 myeloproliferative diseases 60 allergic airway inflammation 60 LY# [003] 60 GPx 60 androgen receptor antagonist 60 somatostatin receptor 60 acetonide FA 60 gastro intestinal inflammation 60 therapeutically relevant 60 DermaVir 60 IGF IR 60 randomized Phase IIb 60 antitumour activity 60 preferentially bind 60 thorough QT 60 mGlu2 3 60 anti fibrotic 60 tumor biopsies 60 PORxin TM 60 antiangiogenic agents 60 ALN PCS 60 pan genotypic 60 tyrosine kinase inhibitor 60 immunoregulatory 60 huN# DM1 60 EGFr expressing metastatic colorectal 60 Topoisomerase II 60 nab paclitaxel 60 TTR gene 60 Phase Ib clinical 60 apoptosis inducing 60 mineralocorticoid 60 ThermoDox ® clinical 60 mimetic compounds 60 engineered RAP peptides 60 LT NS# 60 CANCIDAS 60 metastatic neuroendocrine tumors 60 Phase Ib II 60 Cloretazine VNP#M 59 INSPIRE Trial Phase III 59 Cardiotoxicity 59 Epothilones 59 certain protein tyrosine 59 splice variants 59 Elvitegravir 59 TOLAMBA 59 beta 1a 59 radionuclide therapy 59 paclitaxel poliglumex 59 trastuzumab DM1 T DM1 59 PRTX 59 JAK#/JAK# 59 CCR1 59 rilonacept 59 neuroregenerative 59 bexarotene 59 cathepsins 59 defensin mimetic antibiotic 59 prostate carcinoma 59 LRP5 59 beta lactam antibiotic 59 ALV# 59 DNA intercalator 59 GLYX 59 Immunohistochemical analysis 59 peripherally acting 59 muscarinic 59 THR beta agonist 59 oral anti arrhythmic 59 evaluating Actimmune 59 Iloperidone 59 antiapoptotic 59 ALN VSP 59 desvenlafaxine succinate 59 lipopeptides 59 highly immunogenic 59 leukotriene B4 59 glucagon receptor 59 pan histone deacetylase 59 Aurora Kinase 59 small molecule agonists 59 rituximab Rituxan 59 endothelin receptor 59 RRM1 59 SERMs 59 ketolide antibiotic 59 Phase Ib study 59 TO AVOID PREGNANCY WHILE 59 docetaxel Taxotere ® 59 immatics 59 reslizumab 59 randomized multicenter trial 59 fluoropyrimidine 59 cMET 59 R roscovitine 59 Lixivaptan 59 ixabepilone 59 multicenter randomized controlled 59 recurrent herpes labialis 59 synthetic siRNA 59 highly selective inhibitor 59 vosaroxin 59 evaluating T DM1 59 predictive biomarker 59 abacavir lamivudine 59 Elacytarabine 59 Vaprisol 59 adrenoceptor 59 selective inhibitor 59 phase IIb trial 59 GHRH 59 LB# [003] 59 Amrubicin 59 anaplastic lymphoma kinase ALK 59 Enkephalin 59 budesonide foam 59 antidiabetic 59 ATRA IV 59 thrombopoietin 59 lymphoid malignancies 59 lucinactant 59 pharmacogenomic translational research 59 viral kinetics 59 pharmacodynamic parameters 59 demethylating agents 59 torezolid 59 oral proteasome inhibitor 59 vascular disrupting agents 59 Pyridorin 59 Pazopanib 59 Panzem 59 proteasome inhibition 59 Cytoxan 59 Phase #/#a 59 HuMax CD4 59 anti angiogenic agents 59 Phase 2a trial 59 sodium glucose cotransporter 59 5 HT1A receptor 59 HSP# inhibitor 59 Sipuleucel T 59 radezolid 59 promoter methylation 59 antitumor effect 59 favorable pharmacokinetic 59 MCSP respectively 59 adipogenic 59 lymphoid tumors 59 samalizumab 59 NMDA antagonist 59 BiTE 59 KSP inhibitor 59 selective adenosine 59 Vidaza azacitidine 59 PPARγ 59 tezampanel NGX# 59 EGFR antibodies 59 PROSTVAC VF 59 BAL# [002] 59 poly ICLC 59 bispecific 59 pharmacologically active isomer 59 PEGylated interferon 59 histone deacetylases 59 HIF PH inhibitors 59 promising anticancer 59 murine model 59 evaluating picoplatin 59 Aflibercept 59 adenoviral vectors 59 Phase 2b Clinical Trial 59 randomized controlled Phase 59 GLP toxicology studies 59 Psoraxine R 59 Romidepsin 59 EGFR receptor 59 MGCD# [001] 59 multi kinase inhibitor 59 ritonavir boosted protease inhibitor 59 trial evaluating PRX# 59 BARACLUDE R 59 HIV integrase inhibitors 59 pharmacokinetic characteristics 59 IMPDH inhibitor 59 Imetelstat 59 phase Ib clinical 59 clonidine hydrochloride 59 essential thrombocythemia ET 59 HER2 positive cancers 59 refractory prostate cancer 59 antiresorptive 59 #HT#A 59 binds selectively 59 Fulvestrant 59 apoptosis proteins 59 Toxicities 59 Anticalins R 59 deforolimus 59 pyrimidine nucleoside analog 59 INCB# [001] 59 gastrointestinal stromal tumors GISTs 59 ARIKACE ™ 59 VEGF receptor 59 selective adhesion molecule 59 cytostatic 59 DACH platinum 59 Panzem R 59 recurrent metastatic ovarian cancer 59 BN# [002] 59 radiolabeled 59 selectively inhibits 59 Alfacell proprietary ribonuclease 59 inverse agonist 59 boosted protease inhibitor 59 Selzentry Celsentri 59 anticancer therapies 59 Prodarsan ® 59 hemagglutination inhibition HAI 59 vivo validation 59 Phase 2b clinical 59 rhITF 59 proprietary polysaccharide 59 GSK# [002] 59 monoclonal antibody MAb 59 genomic biomarkers 59 oxysterols 59 Maribavir 59 G#DT 59 bortezomib Velcade ® 59 elacytarabine 59 immune modulator 59 tryptase 59 hydroxychloroquine 59 anthracycline chemotherapy 59 pain palliation 59 DCCR 59 somatostatin analogue 59 DepoVax 59 Sym# 59 androgen independent 59 recombinant subunit vaccine 59 Vaxfectin ® 59 Factor VIIa 59 OVATURE 59 Cytotoxic 59 intratumoral injection 59 platinum chemotherapeutic 59 Myolimus 59 pancreatic prostate 59 Aganocide 59 Orally administered 59 tumor vascular disrupting 59 Raltegravir 59 T#I [002] 59 prokinetic agent 59 novel histone deacetylase 59 intranasal formulation 59 histamine dihydrochloride 59 microdose 59 XOMA 3AB